CD274 and neoplasm: On the basis of these findings, we believe that combination therapy of Pxl, and possibly its derivatives, with ICIs should be tailored in way that takes into account that low doses of Pxl are indeed sufficient to induce a proinflammatory cascade, so that even poorly inflamed, “cold”, tumors can be turned into “hot” tumors increasing the recruitment of immune cells in the tumor microenvironment, but at the same time low Pxl doses are as well able to upregulate immune checkpoint proteins like PD-L1 that would, on the contrary, block adaptive immunosurveillance (33–35).